Atea Pharmaceuticals, Inc. (AVIR) — SEC Filings
Atea Pharmaceuticals, Inc. (AVIR) — 35 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 13 8-K, 8 SC 13G/A, 6 10-Q.
View Atea Pharmaceuticals, Inc. on SEC EDGAR
Overview
Atea Pharmaceuticals, Inc. (AVIR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Atea Pharmaceuticals, Inc. (AVIR) reported a net loss of $42.049 million for the three months ended September 30, 2025, an increase from the $31.151 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $113.482 million, an improvement from $134.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant filing sentiment for Atea Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Atea Pharmaceuticals, Inc. (AVIR) has filed 6 10-Q, 13 8-K, 2 DEF 14A, 4 DEFA14A, 2 10-K, 8 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of AVIR's 28 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$42.049M |
| Cash Position | $329.3M |
Key Executives
- Maria Arantxa Horga
- Abigail P. Johnson
Industry Context
The antiviral drug market, particularly for Hepatitis C, is characterized by significant innovation and competition. Companies are focused on developing more effective, safer, and convenient treatment regimens. Regulatory bodies like the FDA maintain stringent approval processes, requiring robust clinical data.
Top Tags
financial-reporting (7) · sec-filing (7) · corporate-governance (4) · 10-Q (4) · proxy-statement (4) · Pharmaceuticals (3) · financial-condition (3) · pharmaceuticals (3) · Atea Pharmaceuticals (3) · institutional-ownership (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $42.049M | Increased from $31.151M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $113.482M | Improved from $134.842M in the prior year period |
| Research and development expenses for Q3 2025 | $38.347M | Increased from $26.159M in Q3 2024 |
| Cash, cash equivalents, and marketable securities as of Sept 30, 2025 | $329.3M | Sufficient to fund operations for at least twelve months |
| Shares of common stock outstanding as of Nov 10, 2025 | 78,126,796 | Decreased from 84,463,059 shares at Dec 31, 2024 |
| Repurchase of common stock for nine months ended Sept 30, 2025 | $25.519M | Indicates share buyback activity |
| Revenue | $0 | No revenue reported for Q2 2025 and H1 2025, indicating clinical-stage status. |
| Net Loss (Q2 2025) | $45.2M | Decreased from $58.7M in Q2 2024, showing improved financial efficiency. |
| Net Loss (H1 2025) | $90.1M | Decreased from $116.5M in H1 2024, reflecting overall reduced expenses. |
| R&D Expenses (Q2 2025) | $34.8M | Reduced from $47.8M in Q2 2024, primarily due to lower external clinical and manufacturing costs. |
| G&A Expenses (Q2 2025) | $10.4M | Slightly decreased from $10.9M in Q2 2024, contributing to the narrower net loss. |
| Reporting Period | Q1 2025 | The financial and operational data covers the first quarter of 2025. |
| Period End Date | March 31, 2025 | The 10-Q report is for the period ending on this date. |
| Filing Date | May 12, 2025 | The date the 10-Q was officially submitted to the SEC. |
| Fiscal Year | 2024 | Reporting period for executive compensation details. |
Forward-Looking Statements
- {"claim":"FMR LLC will continue to hold a significant, albeit potentially fluctuating, stake in Atea Pharmaceuticals, reflecting their long-term investment strategy.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Atea Pharmaceuticals, Inc. (AVIR)?
Atea Pharmaceuticals, Inc. has 35 recent SEC filings from Jan 2024 to Nov 2025, including 13 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AVIR filings?
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Atea Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Atea Pharmaceuticals, Inc. (AVIR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Atea Pharmaceuticals, Inc.?
Key financial highlights from Atea Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AVIR?
The investment thesis for AVIR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Atea Pharmaceuticals, Inc.?
Key executives identified across Atea Pharmaceuticals, Inc.'s filings include Maria Arantxa Horga, Abigail P. Johnson.
What are the main risk factors for Atea Pharmaceuticals, Inc. stock?
Of AVIR's 28 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Atea Pharmaceuticals, Inc.?
Recent forward-looking statements from Atea Pharmaceuticals, Inc. include guidance on {"claim":"FMR LLC will continue to hold a significant, albeit potentially fluctuating, stake in Atea Pharmaceuticals, re.